AMARIN CORP PLC -ADR (AMRN) Stock News
NASDAQ:AMRN - Nasdaq - US0231112063 - ADR - Currency: USD
AMRN Latest News, Press Relases and Analysis
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call...
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
Amarin Receives National Reimbursement for VAZKEPA® in Italy
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1...
Amarin Receives National Reimbursement for VAZKEPA® in Italy
AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024
AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Amarin Appoints Peter Fishman Chief Financial Officer
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company...
Amarin Appoints Peter Fishman Chief Financial Officer
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company
Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript
AMRN earnings call for the period ending September 30, 2024.
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Amarin Announces Two Upcoming Investor Events
-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November...
Amarin Announces Two Upcoming Investor Events
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or...
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded...
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
AMRN earnings call for the period ending June 30, 2024.
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting...
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
3 Breakthrough Stocks Under $10 Set for Massive Upside
Discover the top breakthrough stocks under $10 with strong fundamentals and strategic advantages to hit massive upside.
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in...
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call...
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in...
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Amarin Board of Directors Announces CEO Transition
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- ...
Amarin Board of Directors Announces CEO Transition
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients...
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s...
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Amarin Reports First Quarter 2024 Business Update and Financial Results
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue...